Cargando…
Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic driver in NSCLC. There seems to be a differential...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474217/ https://www.ncbi.nlm.nih.gov/pubmed/34589933 http://dx.doi.org/10.1016/j.jtocrr.2020.100037 |